Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.

Abstract: Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or onto bleeding tissue of an animal or human. The hydrophobic qualities of the carrier medium can protect the styptic agent from absorbing moisture. The carrier medium can mechanically support positioning treatments adjacent to the bleeding tissue. The carrier medium can further serve to mechanically seal the tissue to aid in hemostasis while also protecting the tissue from debris and contamination. The carrier medium can aid in maintaining moisture within the tissue. Slurry-based manufacturing processes can support a substantially homogeneous dispersal of styptic agent throughout the carrier medium.

Abstract: This invention relates to a cold infusion process for fortifying corn and/or soybeans with one or more vitamin, non-vitamin, mineral, non-mineral, botanical, hormone, herb, neutraceutical, lipid, carbohydrate, amino acid, acid, salt, prebiotic, or probiotic functional additives. This invention also discloses an infused corn and/or soybean produced by the process of infusing the corn and/or soybean at a temperature of less than about 120° F. with a solution comprising water, a bridge initiator for acid salt bias, fortifying agent(s), and an acid in a quantity sufficient to reach a pH of about 3.65. Further, this invention provides a method for the infusion of a corn and/or soybean with at least one fortifying agent at approximately room temperature.

Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.

Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.

Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and citrulline. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, ?-keto-glutarate, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.

Abstract: Nutritional compositions having dietary nucleotides, ?-3 fatty acids and citrulline are provided. The nutritional compositions may be formulated to improve T cell function, increase arginine availability in vivo, regulate myeloid-derived suppressor cells (“MDSC”), and decrease the risk and/or severity of infection after surgery or trauma. Methods of making, using and administering such nutritional compositions to individuals in need of same are also provided. Methods for modulating the affects of MDSC's are also provided.

Abstract: The present invention present a novel and cost-effective family of cosmetic compositions comprising inter alia small magnetic particles characterized by magnetic field adapted to be topically administrated adjacent to skin surface, absorbed to epidermal upper skin layers and place in a direct contact to the body, usually above pain suffering regions. The present invention also provides the use of the compositions, especially of nano-powders of salts obtained from the Dead Sea, as an external layer of bandages, dressings, compresses or warps, so constantly approached to be in an intimate contact with the patient's skin.

Abstract: Novel formulations containing a non-oxidative biocide, such as DBNPA, and a source of an in situ produced active biocide, such as a concentrated aqueous solution of an inorganic halide salt, are disclosed. These novel formulations are particularly effective in the treatment of water, and are characterized by high stability, desirable rheological properties and an excellent biocidal activity.

Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.

Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.

Abstract: The subject matter of the present invention is in particular the use of an amino acid sequence of IDE, or of an analogue or fragment thereof, or of at least one nucleic acid sequence encoding this sequence, as a biomarker, or as an active agent, with regard to a dandruff condition of the scalp.

Abstract: Methods of preparing bioactive composites are described. Also described are methods of molding such composites. Shaped bodies comprising bioactive composites are further described.

Abstract: The present invention is based on that local administration of lithium ions in bone tissue has been found to improve the bone formation and bone mass upon implantation of a bone tissue implant in said bone tissue. In particular, the invention relates to a bone tissue implant having an implant surface covered by an oxide layer comprising lithium ions and a method for the manufacture thereof. A blasting powder comprising lithium ions, a method for locally increasing bone formation, and the use of lithium ions or a salt thereof for manufacturing a pharmaceutical composition for locally increasing bone formation are also provided by the present invention.

Abstract: The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).

Abstract: The present invention provides compositions comprising silicon and at least one other joint health ingredient such as glucosamine, chondroitin, hyaluronic acid, collage, etc. as well as methods for making and using the same.

Abstract: The present invention generally relates to new plant elicitor compositions, and the use of these compositions in agricultural applications, more particularly to protect plants against (infection by) plant pathogens and the corresponding methods of, and uses in, the protection of plants and crops by application of these compositions.

Abstract: A process for producing aqueous chlorous acid solution in which chlorous acid, which is safe for the human body, is easy to handle, and less generates chlorine dioxide, is yielded and used as a disinfectant for a pretreatment in food processing. To an aqueous sodium chlorate solution is added sulfuric acid or an aqueous solution thereof in such an amount and concentration that the pH of the aqueous solution can be kept at 2.3-3.4 to thereby react them and generate chloric acid. Subsequently, hydrogen peroxide is added to the chloric acid in an amount which is equal to or larger than the amount necessary for a reduction reaction to thereby yield chlorous acid. Any one of inorganic acids, inorganic acid salts, organic acids, and organic acid salts, or two or more thereof, or a combination or these is added to the aqueous solution containing chlorous acid yielded, whereby the chlorous and acid can be present for long and the pH of the aqueous solution is regulated to regulated to 3.2-7.0.

Abstract: The invention includes convenient methods of preparing: (1) highly concentrated liquid bromine-containing biocidal solutions, (2) highly concentrated mixed halogen liquid bromine and chlorine-containing biocidal solutions, and (3) high-activity bromine-containing biocidal solids, all having excellent physical and chemical stability. One method yields solutions that have concentrations of bromine in excess of 18% as Br2 (8% as Cl2) in which the mole ratio of hydroxide ion to hydrogen ion source is at least 1.9:1. Another method employs elemental bromine in conjunction with a solid organic or inorganic halogenating agent to yield halogen solutions at concentrations greater than 22.9% as Br2 (10.2% as Cl2). This method can be performed under conditions that exceed the solubility of the active ingredient such that it crystallizes and is recovered as a hydrated or anhydrous salt in good yield.

Abstract: Embodiments herein generally relate to methods and compositions for diagnosing and treating congenital muscle diseases (e.g. muscle myopathy disorders). In certain embodiments, methods and compositions generally relate to treating a subject having a muscle myopathy disorder with a dietary supplement and/or sulfonylurea agent.

Abstract: Disclosed are oral rehydration compositions with sucrose, sodium, chloride, and citric acid or citrate. The composition further comprises an osmolarity of below 250 mOsm/L, and sodium below 75 meq/L. Further disclosed are methods of treatment using the same.

Abstract: The invention relates to the field of agriculture. It concerns an unexpected synergistic activity resulting from a combined use of peracetic acid and at least one SAR inducer which is a water soluble silicate salt defining a source of silicate ions, for the control of pathogens into and on a plant tissue of a growing plant. Also, the invention relates to a water soluble mixture or composition (especially a powdered composition) comprising a peracetic precursor system and at least one SAR inducer which is a water soluble silicate salt defining a source of silicate ions, which once admixed with water, allow the control of pathogens in and onto a plant tissue of a growing plant. Also, the invention relates to uses and methods involving said water soluble mixture or composition, and a kit comprising said water soluble mixture or composition.

Abstract: Methods of processing four-legged animals are described. The methods comprise contacting exterior surfaces of the live animal at least once when the animal is en route to being slaughtered but before it is killed by exsanguination, with a microbiocidal solution. The microbiocidal solution is comprised of: water having a bromine residual derived from (a) (i) at least one bromine source, (ii) at least one alkali metal base, and/or at least one alkaline earth metal base, and (iii) at least one halogen stabilizer; (b) (i) ammonium bromide, and/or at least one alkali metal bromide, and/or at least one alkaline earth metal bromide, and (ii) at least one alkali metal hypohalite and/or at least one alkaline earth metal hypohalite; or (c) a mixture or combination of any one or more of (a) and/or (b); the bromine residual in each of (a), (b), and (c) sufficient to provide microbiocidal activity.

Abstract: New electrical producing creams are provided. In one embodiment, the electrical producing creams comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA. In another embodiment, the electrical producing creams comprise potassium and a source of oxygen supplemented with optional active and inactive ingredients. The most preferred source of oxygen is a chlorite (e.g., sodium chlorite) and/or spirulina. The electrical producing creams provide high metabolic activities and sustain those activities over prolonged periods of time, thus being useful for treating a large variety of ailments, including diabetic neuropathy, post hepatic neuralgia, scleroderma, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain (arthralgia), and edema.

Abstract: A method for treating a wound, and a dressing for wound care management comprising a three-dimensional body of glass-based fibers comprising one or more glass-formers selected from the group consisting of P2O5, SiO2, and B2O3; at least about 25 wt % of the fibers have a diameter between about 200 nm and about 4000 nm, and a length:width aspect ratio of at least about 10. In another form, the glasses are in the form of particles in an ointment or cream applied to a wound. In yet other forms the glasses are employed as fibers formed into sutures for closing a wound, or as particles in a surgical glue for closing a wound.

Abstract: A phase change formulation includes a reversible phase change material and a thermal conductivity additive formulated for application to a user's epidermis.

Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.

Abstract: The presenting invention is directed to methods and compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and methods for administering the compositions to treat various neuropathies.

Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.

Abstract: A skin smoothing composition that has from about 0.5 to about 4% sodium silicate as measured by silica content (SiO2) and from about 0.1% to about 4.0% of a polyvalent silicate. The composition is provided in a carrier, for example, from about 10 to 98% water, and can be in the form of a water gel or oil-in-water emulsion. Further, the weight ratio of sodium silicate to the polyvalent silicate is equal to or greater than 0.7. and the polyvalent silicate is a silicate clay selected from the group consisting of bentonite, laponite, smectite, and kaolinite. Kits containing these compositions and methods of using these compositions are also provided.

Abstract: The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Abstract: A method for smoothing skin comprising applying a composition that has from about 0.5 to about 4% sodium silicate as measured by silica content (SiO2) and from about 0.1% to about 4.0% of a polyvalent silicate. The composition is provided in a carrier, for example, from about 10 to 98% water, and can be in the form of a water gel or oil-in-water emulsion. A second composition is applied before or after the first composition wherein the second composition is selected from the group consisting of an oil-in-water emulsion, water-in-oil emulsion, thickened water gel, thickened oil phase, encapsulated oil phase, solid oil phase, and mixtures thereof. The polyvalent silicate can be a silicate clay selected from the group consisting of bentonite, laponite, smectite, and kaolinite.

Abstract: Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine.

Abstract: A biological decontamination gel, consisting of a colloidal solution comprising from 5 to 30% by mass, preferably 5 to 25% by mass, still preferably 8 to 20% by mass, based on the mass of the gel, of at least one inorganic viscosifying agent: 0.5 to 10 mol/L of gel, preferably 1 to 10 mol/L of gel, of at least one active biological decontamination agent; 0.05 to 5% by mass, preferably 0.05 to 2% by mass, based on the mass of the gel, of at least one super-absorbent polymer; 0.1 to 2% by mass, based on the mass of the gel, of at least one surfactant; and the remainder of solvent. A biological decontamination method applying this gel.

Abstract: The method of treating impaired wound healing in diabetics comprises the step of administering an effective amount of a glycogen synthase kinase 3-? (GSK-3?) inhibitor to a diabetic patient in need thereof to activate the NF-E2-related factor 2 (Nrf2) and genes downstream of Nrf2 that normally regulate the expression and coordination of antioxidant responses during wound healing, but are suppressed in the diabetic patient undergoing the oxidative stress that can occur during wound healing. The GSK-3? inhibitor may be lithium or a pharmaceutically acceptable salt thereof, or TDZD-8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione). The method may further comprise the step of testing the diabetic patient for the presence of oxidative stress and decreased Nrf2, which enables the early or prophylactic treatment of the patient with a GSK-3? inhibitor when the patient first presents with a wound, rather than waiting for other symptoms of impaired wound healing to occur.

Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.

Abstract: The present invention relates to an oil-in-water emulsion comprising at least one mucomimetic polymer, at least one lipid of phospholipid type, at least one lipid other than the phospholipid, at least one stabilizing polymer, and a hydrophilic liquid, to an emulsion comprising an aqueous phase that contains at least one stabilizing polymer and at least one mucomimetic polymer, and an oily phase that contains at least one lipid of phospholipid type and a lipid other than the phospholipid, to a medicament comprising one of these emulsions, and to the use of one of these emulsions as an agent for restoring and/or replacing the lachrimal film or as a carrier for an active compound.

Abstract: The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating spinal cord injury, tissue remodeling, and promoting bone growth and repair.

Abstract: The present invention relates to dissolved silicate compositions in which the dissolved silicate is stabilized by at least two selected osmolytes and is therefore bioavailable. The composition and its dilutions are stable over a long period of time and are used in a wide field of applications for the benefit of living organisms such as plants, animals and humans.

Abstract: Cements containing certain small molecule amino acid phosphate compounds such as phosphoserine and certain multivalent metal compounds such as but not limited to calcium phosphate have been found to have improved properties and form a macromolecular network in the presence of a bioactive glass material that contain silicates, phosphates, and calcium salts which can be involved in the formation of bonding sites.

Abstract: Provided is to enhance the therapeutic effect of an iontophoretic preparation for treatment of breast cancer or mastitis. An iontophoretic preparation for treatment of breast cancer and/or mastitis containing, as an active ingredient, a nonsteroidal anti-inflammatory analgesic agent and/or an anticancer agent, wherein an electrolyte is topically administered through the nipple part into the mammary gland; subsequently, a donor is applied to the nipple part; and the active ingredient is topically administered through the nipple part into the mammary gland by application of current.

Abstract: Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat nephropathy, and methods for preparing activated fatty acids are provided herein.

Abstract: A kit for colonic cleansing includes a phosphate salt laxative, a flavorant, and an oral rehydration mixture. The flavorant includes aspartame and a citrate, and the oral rehydration mixture includes sodium and a glucose containing saccharide. The kit may be used for a colonic cleansing procedure by combining the phosphate salt laxative and the flavorant to provide a flavored laxative liquid, orally administering to a subject the flavored laxative liquid, and orally administering to the subject an oral rehydration liquid.

Abstract: The bone graft system comprises a solid inorganic component, which is bone graft material, and a hydrogel. The hydrogel contains >2 ppm of silicon ions, calculated as parts by weight of Si per million of the aqueous component of the hydrogel. Preferably, the solid inorganic component comprises hydroxyapatite or a silicon-containing hydroxyapatite, and may be a silicon-containing hydroxyapatite having a Ca/P ratio in the range 2.05 to 2.55 and a Ca/(P+Si) molar ratio less than 1.66. Bone healing is promoted by delivery of silicon ion release from the hydrogel and by the solid inorganic component stimulating cell behavior.

Abstract: The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

Abstract: A composition comprises an ion-exchanged carrageenan. The carrageenan may be a traditionally extracted or neutrally extracted iota or kappa carrageenan. The ion-exchanged carrageenan has reduced gelling cation contents, reduced gelling temperature, and reduced melting temperature, as compared to its non-ion-exchanged counterpart. The ion-exchanged carrageenan may be mixed with another carrageenan to form a carrageenan product having a unique gelling temperature and melting temperature. Also disclosed is a process for making an ion-exchanged carrageenan composition.

Abstract: A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.

Abstract: The present invention relates to an inhibitor of glycogen synthase kinase 3 (GSK-3) for use in a method of treating or preventing emphysema, a method of activating an emphysema cell, an activated emphysema cell obtained by this method for use in a method of treating or preventing emphysema, and a method of screening for a substance for treating or preventing emphysema.